What to Expect: Survivorship, Monitoring, and Ongoing Care
At a Glance
After surgery for gallbladder or biliary tract cancer, survivorship involves regular monitoring with scans and CA 19-9 blood tests to check for recurrence. Long-term care also focuses on managing potential complications like biliary strictures, nutritional deficiencies, and scanxiety.
Moving from the intensive phase of treatment into survivorship is a major milestone, but it often brings a new set of challenges. Transitioning from frequent doctor visits to a schedule of “watchful waiting” can feel like losing a safety net. Understanding what to expect during this phase can help you regain a sense of control over your health and your life [1].
The Surveillance Roadmap
After curative-intent surgery, your medical team will monitor you closely to catch any potential recurrence as early as possible. While every plan is personalized based on your specific risk factors, a typical schedule looks like this:
- Years 1–2: This is the highest-risk period for recurrence. You will likely have physical exams, blood work (including CA 19-9), and cross-sectional imaging (CT or MRI) every 3 to 6 months [1][2].
- Years 3–5: If the cancer has not returned, the frequency usually stretches out to every 6 to 12 months [1].
- Beyond 5 Years: While some centers stop formal surveillance at five years, many doctors continue annual check-ins, as late complications or recurrences can occasionally occur [1][3].
Monitoring with CA 19-9: Facts and Flaws
CA 19-9 is a protein (tumor marker) often found in the blood of people with biliary tract cancers. While it is a helpful tool, it is not a perfect “cancer detector” [4][5].
- Baseline Matters: The most important use of CA 19-9 is comparing your current level to your post-surgery “baseline” [6][7].
- The Obstruction Effect: Non-cancerous issues like a blocked bile duct, a stone, or cholangitis (infection) can cause CA 19-9 to skyrocket. An elevated number does not always mean the cancer is back [8][5].
- Non-Secretors: About 5–10% of the population lacks the “Lewis antigen” needed to produce CA 19-9. In these patients, the marker will always be low, even if cancer is present. If you are a non-secretor, your doctors will rely entirely on imaging [9][10].
Navigating Long-Term Complications
Even after a successful surgery or the placement of a stent, the biliary system remains sensitive. Two common long-term issues include:
- Biliary Strictures: These are narrowings that can form where the bile duct was reconstructed (the anastomosis). These can cause bile to back up, leading to jaundice or itching [11][12].
- Nutritional Changes: Because bile is essential for absorbing fats, surgery can sometimes lead to deficiencies in fat-soluble vitamins (A, D, E, and K). These deficiencies are typically managed with specialized, high-dose supplements prescribed by a clinical dietitian or GI doctor [13].
Managing “Scanxiety” and the Psychological Toll
The “waiting game” of follow-up scans can trigger a unique form of distress often called scanxiety.
- The Psychological Gap: While research often focuses on physical survival markers like sarcopenia (muscle loss), the emotional reality of living as a survivor is just as significant [13][14].
- Coping Strategies: Many survivors find it helpful to schedule scans on Mondays so they don’t have to wait through a weekend for results, or to bring a “point person” to appointments to help record information when anxiety makes it hard to focus.
survivorship is a shift in perspective. While you are no longer in “crisis mode,” you are now an active partner in long-term monitoring, ensuring that you and your team are ready for whatever comes next [1][15].
Common questions in this guide
How often will I need scans after biliary cancer surgery?
What does an elevated CA 19-9 level mean during survivorship?
What does it mean to be a CA 19-9 non-secretor?
Why might my doctor check my vitamin levels after gallbladder surgery?
What are the signs of a biliary stricture or infection?
Get notified when new evidence is published on Carcinoma of gallbladder and extrahepatic biliary tract.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.
References
References (15)
- 1
Evaluation of Tumor Markers and Their Impact on Prognosis in Gallbladder, Bile Duct and Cholangiocellular Carcinomas - A Pilot Study.
Liska V, Treska V, Skalicky T, et al.
Anticancer research 2017; (37(4)):2003-2009 doi:10.21873/anticanres.11544.
PMID: 28373474 - 2
Recurrence after curative-intent resection of perihilar cholangiocarcinoma: analysis of a large cohort with a close postoperative follow-up approach.
Komaya K, Ebata T, Yokoyama Y, et al.
Surgery 2018; (163(4)):732-738 doi:10.1016/j.surg.2017.08.011.
PMID: 29336813 - 3
Common bile duct stone development due to a Hem-o-lok clip migration: a rare complication of laparoscopic cholecystectomy.
Roh YJ, Kim JW, Jeon TJ, Park JY
BMJ case reports 2019; (12(7)) doi:10.1136/bcr-2019-230178.
PMID: 31352393 - 4
Clinical significance of CA 19-9 elevation during postoperative surveillance for extrahepatic bile duct cancer: a nomogram-based approach for the prediction of short-term recurrence.
Kwon YJ, Min JH, Hwang JA, et al.
HPB : the official journal of the International Hepato Pancreato Biliary Association 2025; (27(2)):195-205 doi:10.1016/j.hpb.2024.10.015.
PMID: 39586759 - 5
Carbohydrate Antigen (CA 19-9) Surge: Unraveling the Enigma of Elevated Levels in the Setting of Benign Etiologies.
Ansari N, Ozgur SS, Besada D, et al.
Cureus 2024; (16(4)):e57469 doi:10.7759/cureus.57469.
PMID: 38699139 - 6
Importance of Normalization of Carbohydrate Antigen 19-9 in Patients With Intrahepatic Cholangiocarcinoma.
Li H, Feng Y, Liu C, et al.
Frontiers in oncology 2021; (11()):780455 doi:10.3389/fonc.2021.780455.
PMID: 35004301 - 7
CA 19-9 Surveillance Detects Recurrences Early and Contributes to Improvement in Survival in Resected Ampullary Cancers: Analysis of 572 Cases.
Bhandare MS, Varty GP, Reddy Obili RC, et al.
Annals of surgery 2026; (283(2)):286-296 doi:10.1097/SLA.0000000000006419.
PMID: 38939924 - 8
An Unusual Case of Intrahepatic Stone Masquerading as Cholangiocarcinoma.
Williams AS, Sikes MA, Liu S
ACG case reports journal 2025; (12(2)):e01607 doi:10.14309/crj.0000000000001607.
PMID: 39916889 - 9
KRAS Mutation Allele Frequency Dynamics in Plasma Extracellular Vesicles: Association with Survival in Localized Pancreatic Adenocarcinoma.
Chopra A, He HZ, Milosevic J, et al.
Annals of surgical oncology 2026; (33(2)):1605-1615 doi:10.1245/s10434-025-18633-7.
PMID: 41186643 - 10
Serum Dickkopf-1 in Combined with CA 19-9 as a Biomarker of Intrahepatic Cholangiocarcinoma.
Kim SY, Lee HS, Bang SM, et al.
Cancers 2021; (13(8)) doi:10.3390/cancers13081828.
PMID: 33921232 - 11
Long-term follow-up and risk factors for strictures after hepaticojejunostomy for bile duct injury: An analysis of surgical and percutaneous treatment in a tertiary center.
Booij KAC, Coelen RJ, de Reuver PR, et al.
Surgery 2018; (163(5)):1121-1127 doi:10.1016/j.surg.2018.01.003.
PMID: 29475612 - 12
Open injury, robotic repair-moving ahead! Total robotic Roux-en-Y hepaticojejunostomy for post-open cholecystectomy Bismuth type 2 biliary stricture using indocyanine green dye.
Rathore KS, Varshney P, Soni SC, et al.
Journal of minimally invasive surgery 2023; (26(3)):151-154 doi:10.7602/jmis.2023.26.3.151.
PMID: 37712315 - 13
Preoperative Myosteatosis and Prognostic Nutritional Index Predict Survival in Older Patients With Resected Biliary Tract Cancer.
Utsumi M, Inagaki M, Kitada K, et al.
Cancer diagnosis & prognosis 2024; (4(2)):147-156 doi:10.21873/cdp.10301.
PMID: 38434914 - 14
Biliary tract cancer.
Valle JW, Kelley RK, Nervi B, et al.
Lancet (London, England) 2021; (397(10272)):428-444 doi:10.1016/S0140-6736(21)00153-7.
PMID: 33516341 - 15
Conditional Recurrence-Free Survival for Patients with Gallbladder Cancer: A Personalized Resource for Patients and Providers.
Ejaz A, Pawlik TM
Annals of surgical oncology 2021; (28(5)):2436-2437 doi:10.1245/s10434-021-09629-0.
PMID: 33528709
This page provides general information about gallbladder and biliary tract cancer survivorship. It is for educational purposes only and should not replace personalized advice from your oncology team.